公开(公告)号：US6099730A

公开(公告)日：2000-08-08

申请号：US191175

申请日：1998-11-13

申请人： Guillermo Ameer ,  Rober S. Langer, Jr. ,  Maria Rupnick ,  Hidde L. Ploegh ,  Eric Grovender

发明人： Guillermo Ameer ,  Rober S. Langer, Jr. ,  Maria Rupnick ,  Hidde L. Ploegh ,  Eric Grovender

IPC分类号： A61M1/16 ,  A61M1/20 ,  A61M1/26 ,  A61M1/34 ,  A61M1/36 ,  A61M1/38 ,  B01D61/00 ,  B01D63/16 ,  B01D65/08 ,  B01D33/00 ,  B01D63/00

CPC分类号： B01D65/08 ,  A61M1/16 ,  A61M1/265 ,  A61M1/3437 ,  A61M1/3472 ,  A61M1/3475 ,  A61M1/3486 ,  A61M1/3489 ,  A61M1/3679 ,  A61M1/38 ,  B01D61/00 ,  B01D63/16 ,  A61M2202/0407 ,  A61M2202/0415 ,  A61M2202/0421 ,  A61M2202/0427 ,  B01D2321/20 ,  B01D2321/2058

摘要： Apparatus for removing substances from blood is disclosed. The apparatus includes concentric cylinders defining an annulus therebetween with the inner cylinder adapted for rotation with respect to the outer cylinder. At least one of the cylinders includes a porous membrane covered portion forming a compartment containing an immobilized active species. The active species is adapted to break down or remove the substance. Plasma in blood flowing in the annulus passes through the porous membrane and interacts with the active species either by reaction or binding. Red and white blood cells do not pass through the membrane. In this way, a substance is removed from plasma without exposing blood cells to the active species.

摘要翻译： 公开了从血液中去除物质的装置。 该装置包括在其间限定环形的同心圆筒，其中内筒适于相对于外筒旋转。 至少一个气缸包括形成包含固定的活性物质的隔室的多孔膜覆盖部分。 活性物质适于分解或除去物质。 在环中流动的血液中的血浆通过多孔膜并通过反应或结合与活性物质相互作用。 红细胞和白细胞不通过膜。 以这种方式，将物质从血浆中除去而不将血细胞暴露于活性物质。

公开(公告)号：US06306819B1

公开(公告)日：2001-10-23

申请号：US09183556

申请日：1998-10-30

申请人： Maria Rupnick ,  Robert S. Langer ,  Judah Folkman

发明人： Maria Rupnick ,  Robert S. Langer ,  Judah Folkman

IPC分类号： A61K3800

CPC分类号： A61K38/484 ,  A61K31/00 ,  A61K31/336 ,  A61K31/454 ,  A61K38/39

摘要： Angiogenesis inhibitors are administered to patients in an amount effective to regulate normal, non-transformed vascularized tissue size and/or growth by regulating its vascular compartment. Examples of tissues that can be controlled include adipose tissue, intestinal polyps, muscle (including cardiac) tissue, and endometrial tissue. The response of these tissues to the angiogenesis inhibitors is dose-dependent, reversible, and common to a variety of different angiogenesis inhibitors (examples use TNP-470, angiostatin, and endostatin), based on studies in animal models of obesity, intestinal polyps, cardiac hypertrophy, and endometriosis. Initial studies conducted in an adipose tissue model (genetically obese mice and normal control mice) showed that the growth and mass of adipose tissue is under the control of microvascular endothelium. Expansion of adipose tissue was associated with endothelial cell proliferation. Inhibition of angiogenesis led to reduction in adipose tissue mass. Weight gain in animals receiving angiogenesis inhibitors was significantly restricted, in spite of increases in appetite sufficient to cause weight gain in paired-fed mice. Discontinuation of the inhibitor resulted in rapid expasion of the adipose tissue. The effect was dose-dependent, repeatedly reversible, and occurred in response to all of the inhibitors tested. Significant inhibition was also observed in both the intestinal polyp and cardiac hypertrophy animal models, using dosages of two-thirds or less than the dosages used to treat tumors. Preliminary results in an endometriosis model also show a clear trend towards decreased development of endometriosis in animals treated with angiogenesis inhibitors at a dosage of one-third the dosage used to treat tumors. No effect on normal tissue that was not proliferating, other than adipose tissue, was observed.

摘要翻译： 血管生成抑制剂以有效调节正常，非转化的血管化组织尺寸和/或通过调节其血管隔室生长的量施用于患者。 可以控制的组织的实例包括脂肪组织，肠息肉，肌肉（包括心脏）组织和子宫内膜组织。 这些组织对血管生成抑制剂的反应是剂量依赖性的，可逆的，并且对多种不同的血管发生抑制剂是常见的（实例使用TNP-470，血管抑素和内皮抑制素），基于对肥胖，肠息肉动物模型的研究， 心脏肥大和子宫内膜异位症。 在脂肪组织模型（遗传肥胖小鼠和正常对照小鼠）中进行的初步研究表明，脂肪组织的生长和质量处于微血管内皮的控制之下。 脂肪组织的扩张与内皮细胞增殖有关。 抑制血管生成导致脂肪组织质量下降。 接受血管生成抑制剂的动物的体重增加受到显着限制，尽管食欲增加足以引起配对饲喂小鼠的体重增加。 抑制剂的停用导致脂肪组织的快速释放。 该效应是剂量依赖性的，反复可逆的，并且响应所有测试的抑制剂而发生。 在肠息肉和心脏肥大动物模型中也观察到显着的抑制作用，其使用剂量为用于治疗肿瘤的剂量的三分之二或更少。 子宫内膜异位症模型的初步结果也显示出以血管生成抑制剂治疗的动物减少子宫内膜异位症发展的明显趋势，其剂量为用于治疗肿瘤的剂量的三分之一。 观察到除了脂肪组织之外对正常组织没有增殖的影响。